Letters to the Editor
Vol. 17 No. 1 (2025): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Addition of daratumumab to first-line therapy of newly diagnosed multiple myeloma in patients eligible for autologous stem cell transplantation: a single-center real-life experience
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: April 2, 2025
Accepted: April 8, 2025
Accepted: April 8, 2025
927
Views
642
Downloads
124
HTML
Authors
Downloads
Download data is not yet available.
Citations
Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394, 29–38 (2019). https://doi.org/10.1016/S0140-6736(19)31240-1
Eleutherakis Papaiakovou, E. et al. Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 64, 2140–2147 (2023). https://doi.org/10.1080/10428194.2023.2253479
Cavallaro, G. et al. Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis. Mediterr J Hematol Infect Dis 16, e2024049 (2024). https://doi.org/10.4084/MJHID.2024.049
Palumbo, A. et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. Journal of Clinical Oncology 33, 2863–2869 (2015). https://doi.org/10.1200/JCO.2015.61.2267
D’Agostino, M. et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology 364, (2022). https://doi.org/10.1200/JCO.21.02614
Fernández de Larrea, C. et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J 11, (2021). https://doi.org/10.1038/s41408-021-00587-0
Jung, S. H. & Lee, J. J. Update on primary plasma cell leukemia. Blood Res 57, 62 (2022). https://doi.org/10.5045/br.2022.2022033
Rah, S. Y. et al. CD38/ADP-ribose/TRPM2-mediated nuclear Ca2+ signaling is essential for hepatic gluconeogenesis in fasting and diabetes. Exp Mol Med 55, 1492–1505 (2023). https://doi.org/10.1038/s12276-023-01034-9
How to Cite
“Addition of daratumumab to first-line therapy of newly diagnosed multiple myeloma in patients eligible for autologous stem cell transplantation: a single-center real-life experience” (2025) Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025040. doi:10.4084/MJHID.2025.040.
Copyright (c) 2025 Edoardo Olivari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
